Pharmacodynamics of ceftriaxone and cefixime against community-acquired respiratory tract pathogens

International Journal of Antimicrobial Agents

Volumn 17, Issue 6, 2001, Pages 483-489

  Owens Jr , Robert C ^a,b   Tessier, Pamela ^c   Nightingale, Charles H ^c   Ambrose, Paul G ^d   Quintiliani, Richard ^c   Nicolau, David P ^c  

^a MAINE MEDICAL CENTER   (United States)

^b UNIVERSITY OF VERMONT   (United States)

^c HARTFORD HOSPITAL   (United States)

^d Albany Medical College   (United States)

Author keywords

Cephalosporins; Pharmacodynamics; Respiratory tract infections; Serum bactericidal titre; Streptococcus pneumoniae; Transitional therapy

Indexed keywords

CEFIXIME; CEFTRIAXONE; CEPHALOSPORIN DERIVATIVE;

ADULT; ARTICLE; BACTERICIDAL ACTIVITY; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG EFFICACY; HUMAN; HUMAN EXPERIMENT; MINIMUM INHIBITORY CONCENTRATION; NORMAL HUMAN; PHARMACODYNAMICS; PRIORITY JOURNAL; RESPIRATORY TRACT INFECTION; STREPTOCOCCUS PNEUMONIAE;

ADMINISTRATION, ORAL; ADULT; BLOOD BACTERICIDAL ACTIVITY; CEFIXIME; CEFTRIAXONE; CEPHALOSPORINS; COMMUNITY-ACQUIRED INFECTIONS; CROSS-OVER STUDIES; FEMALE; HAEMOPHILUS INFECTIONS; HAEMOPHILUS INFLUENZAE; HUMANS; INJECTIONS, INTRAMUSCULAR; INJECTIONS, INTRAVENOUS; MALE; MORAXELLA (BRANHAMELLA) CATARRHALIS; NEISSERIACEAE INFECTIONS; PNEUMOCOCCAL INFECTIONS; RESPIRATORY TRACT INFECTIONS; STREPTOCOCCUS PNEUMONIAE;

EID: 0034985597     PISSN: 09248579     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0924-8579(01)00322-3     Document Type: Article

References (26)

1. Evaluation of the in vitro activity of cefixime for its use in switch therapy
2. Serum bactericidal activity of ceftizoxime and ceftriaxone against pathogens associated with community-acquired and nosocomial pneumonias
3. Measurement of cefixime in serum and cerebrospinal fluid by high-performance liquid chromatography
4. Determination of cefixime in biological samples by reversed-phase high-performance liquid chromatography
5. Pharmacodynamics of antimicrobial agents as a basis for determining dosage regimens
6. Optimal times above the MIC of ceftibuten and cefaclor in experimental intra-abdominal infections
7. Role for dual individualization with cefmenoxime
8. Relevance of the Alexander Project: pharmacodynamic considerations
9. Interrelationship between pharmacokinetics and pharmacodynamics in determining dosage regimens for broad-spectrum cephalosporins
10. Clinical pharmacokinetics of ceftriaxone
11. Surveillance of antimicrobial resistance in Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis in the United States in 1996-1997 respiratory season
12. The pharmacokinetics of cefixime in the fasted and fed state
13. The serum bactericidal test
14. Serum bactericidal activity against Moraxella catarrhalis and Streptococcus pneumoniae after administration of four oral cephalosporins in healthy volunteers
15. Sequential therapy with intravenous and oral cephalosporins
16. Pharmacokinetic and pharmacodynamic considerations in antibiotic selection with particular attention to oral cephalosporins
17. Serum bactericidal activity of newer oral cephalosporins in healthy volunteers
18. Cost savings resulting from early switch to oral cefixime in hospitalized patients with CAP
19. Early switch from intravenous to oral antibiotics in hospitalized patients with infections: a 6-month prospective study
20. Third generation cephalosporins in the parenteral to oral switch
21. Early switch from intravenous to oral cephalosporins in the treatment of hospitalized patients with community-acquired pneumonia